Physician profile
Brian D Barash
NPI 1689663049
$856,306.70
in general payments reported to CMS, 2019-2025
31 companies · $126K in 2025
The $126K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $70K · 2021: $128K · 2022: $135K · 2023: $175K · 2024: $155K · 2025: $126K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $320K · Honoraria: $49K · Travel and Lodging: $35K · Consulting Fee: $34K · Food and Beverage: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $320,476.54 |
| Honoraria | $48,750.00 |
| Travel and Lodging | $35,362.84 |
| Consulting Fee | $34,185.00 |
| Food and Beverage | $13,825.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $211,984.56 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $122,768.05 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $108,548.36 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $102,058.21 | 2021-2025 | Vraylar |
| Alkermes, INC. | $96,146.53 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Allergan, INC. | $79,664.50 | 2019-2021 | |
| Axsome Therapeutics, INC. | $39,525.19 | 2022-2025 | Auvelity |
| Tris Pharma INC | $35,156.69 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $27,752.61 | 2021-2024 | Azstarys, Azstarys |
| Eisai INC. | $15,665.10 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14,579.53 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $611.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $394.79 | 2019-2023 | Spravato, Invega Sustenna |
| Neos Therapeutics, LP | $279.79 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $207.42 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $202.55 | 2019-2020 | |
| Shire North American Group INC | $133.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.25 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $98.93 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $87.69 | 2019-2024 | |
| Vertical Pharmaceuticals, LLC | $71.52 | 2019 | |
| Brainsway USA INC | $71.36 | 2025 | Deep Tms System |
| Neuronetics, INC. | $48.69 | 2019 | |
| Almatica Pharma LLC | $25.82 | 2023-2024 | Loreev Xr |
| Arbor Pharmaceuticals, INC. | $25.46 | 2019 | |
| Neurocrine Biosciences, INC. | $17.58 | 2019 | |
| Noven Therapeutics, LLC | $15.09 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.70 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.80 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $10.41 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Barash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.